

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)ATTY DOCKET NO.  
18733/734SERIAL NO.  
09/216,609APPLICANT  
Hans J. HANSENFILING DATE  
December 21, 1998GROUP  
1643

Date Submitted to PTO: June 21, 1999

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ALH	A1	4,975,278	12/90	SENER et al.	424	94.3	
ALH	A2	4,762,707	08/88	JANSEN et al.	424	94.3	
ALH	A3	4,472,509	09/84	GANSOW et al.	424	1.1	
ALH	A4	4,975,278	12/90	SENER et al.	424	94.3	

## FOREIGN PATENT DOCUMENTS

	A5	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
ALH	A6	88/073781	10/88	WIPO			
ALH	A7	8 303 679	10/83	WIPO			
ALH	A8	0 217 577	04/87	EUROPE			
ALH	A9	0 382 411	08/90	EUROPE			
ALH	A10	90/07929	07/90	WIPO			
ALH	A11	0 423 747	04/91	EUROPE			
ALH	A12	89/10140	11/89	WIPO			

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

ALH	A13	PHILPOTT et al., "Selective Cytotoxicity of Hapten-substituted Cells With An Antibody-Enzyme Conjugate", <i>The Journal of Immunology</i> , Vol. 111, No. 3, pp. 921-929, (1973)
ALH	A14	PHILPOTT et al., "Affinity Cytotoxicity Of Tumor Cells With Antibody-Glucose Oxidase Conjugates, Peroxidase, and Arsphenamine", <i>Cancer Research</i> , Vol. 34:2159-2164, (1974)
ALH	A15	THORPE, P.E., "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", <i>Monoclonal Antibodies</i> '84: <i>Biological and Clinical Applications</i> , 1985 Editrice Durtis s.r.l., pp. 475-490
ALH	A16	BALDWIN, R.W., "Monoclonal Antibodies In Cancer Treatment", <i>The Lancet</i> , pp.603-605, (1986)
ALH	A17	EMBLETON, M.J., "Targeting Of Anti-Cancer Therapeutic Agents By Monoclonal Antibodies", <i>Biochemical</i> <i>Society Transactions</i> , Vol. 14:393-395

EXAMINER

Anne L. Holleran

DATE CONSIDERED

8/6/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)ATTY DOCKET NO.  
18733/734SERIAL NO.  
09/216,609APPLICANT  
Hans J. HANSENFILING DATE  
December 21, 1998GROUP  
1643

Date Submitted to PTO: June 21, 1999

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
ALH	A18	88/07378	10/88	WIPO		
ALH	A19	0 302 473	02/89	EUROPE		
ALH	A20	87/05031	08/87	WIPO		

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

ALH	A21	Bagshawe, et al., "A cytotoxic agent can be generated selectively at cancer sites", <i>British Journal of Cancer</i> (1988) 58, 700-703
ALH	A22	Dowell, et al., "New Mustard Prodrugs for Antibody-Directed Anzyme Prodrug Therapy: Alternatives to the Amide Link", <i>Journal Of Medicinal Chemistry</i> , 39:5 1100-1105 (1996)
ALH	A23	Svensson, et al., "Synthesis and Characterization of Monoclonal Antibody- $\beta$ -Lactamase Conjugates", <i>Bioconjugate Chem.</i> 5 262-267 (1994)
ALH	A24	Wang, et al., "Specific Activation of Glucuronide Prodrugs by Antibody-targeted Enzyme Conjugates for Cancer Therapy", <i>Cancer Research</i> 52, 4484-4491 (1992)
ALH	A25	Roffler, et al., "Potentiation of Radioimmunotherapy by Inhibition of Topoisomerase I", <i>Cancer Research</i> 54, 1276-1285 (1994)

EXAMINER

Anne L. Holman

DATE CONSIDERED


8/3/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: June 21, 1999

ATTY DOCKET NO.  
018733/0734SERIAL NO.  
09/216,609APPLICANT  
Hans J. HANSENFILING DATE  
December 21, 1998GROUP  
1643

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Cases)

ALH	A26	Tschmelitsch, et al., "Enhanced Antitumor Activity of Combination Radioimmunotherapy ( <sup>131</sup> I-labeled Monoclonal Antibody A33) with Chemotherapy (Fluorouracil)", <i>Cancer Research</i> 57, 2181-2186 (1997)
ALH	A27	Blakey, et al., "ZD2767, an Improved System for Antibody-directed Enzyme Prodrug Therapy That Results in Tumor Regressions in Colorectal Tumor Xenografts", <i>Cancer Research</i> 56, 3287-3292 (1996)
ALH	A28	Sharma, et al., "Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model", <i>British Journal of Cancer</i> , 61, 659-662 (1990)
ALH	A29	Bosslet, et al., "Tumor-selective Prodrug Activation by Fusion Protein-mediated Catalysis", <i>Cancer Research</i> , 54, 2151-2159 (1994)
ALH	A30	Svensson, et al., "In Vitro and In Vivo Activities of a Doxorubicin Prodrug in Combination with Monoclonal Antibody $\beta$ -Lactamase Conjugates", <i>Cancer Research</i> , 55, 2357-2365 (1995)
ALH	A31	Houba, et al., "Improved Characteristics of a Human $\beta$ -Glucuronidase-Antibody Conjugate after Deglycosylation for Use in Antibody-Directed Enzyme Prodrug Therapy", <i>Bioconjugate Chem.</i> , 7, 606-611 (1996)
ALH	A32	Meyer, et al., "Site-specific Prodrug Activation by Antibody- $\beta$ -Lactamase Conjugates: Preclinical Investigation of the Efficacy and Toxicity of Doxorubicin Delivered by Antibody Directed Catalysis", <i>Bioconjugate Chem.</i> , 6, 440-446 (1995)
ALH	A33	Eccles, et al., "Regression of Established Breast Carcinoma Xenografts with Antibody-directed Enzyme Prodrug Therapy against c-erbB2 p185", <i>Cancer Research</i> , 54, 5171-5177 (1994)
ALH	A34	Senter, et al., "Generation of Cytotoxic Agents by Targeted Enzymes", <i>Bioconjugate Chem.</i> , 4, 3-9 (1993)
ALH	A35	Antoniw, et al., "Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice", <i>British Journal of Cancer</i> , 62, 909-914 (1990)
ALH	A36	Sharma, et al., "Antibody Directed Enzyme Prodrug Therapy (ADEOT): A Three Phase System", <i>Disease Markers</i> , 9, 225-231 (1991)
ALH	A37	Kerr, et al., "Application of Monoclonal Antibodies against Cytosine Deaminase for the in Vivo Clearance of a Cytosine Deaminase Immunoconjugate", <i>Bioconjugate Chem.</i> 4, 353-357 (1993)
ALH	A38	Meyer, et al., "Site-specific prodrug activation by antibody-lactamase conjugates: Regression and Long term growth inhibition of human colon carcinoma xenograft models", <i>Cancer Research</i> , 53: 3956-3963 (1993)
EXAMINER	Anne L. Anderson	
DATE CONSIDERED	8/5/00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.